Cargando…

Assessing the association between omalizumab and arteriothrombotic events through spontaneous adverse event reporting

BACKGROUND: Omalizumab is a monoclonal antibody, indicated for the treatment of severe allergic asthma. In Europe, there have been concerns about the cardiovascular safety of omalizumab. The objective of this study was to analyze the association between omalizumab and arterial thrombotic events in a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ali, Ayad K, Hartzema, Abraham G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3363016/ https://www.ncbi.nlm.nih.gov/pubmed/22690127 http://dx.doi.org/10.2147/JAA.S29811

Ejemplares similares

271 Evaluation of Adverse Events Associated to Administration of Omalizumab
por: Gomez, R. Maximiliano, et al.
Publicado: (2012)

Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports
por: Kato, Yamato, et al.
Publicado: (2015)

Adverse Events Related to Off-Label Drugs Using Spontaneous Adverse Event Reporting Systems
por: Han, Nayoung, et al.
Publicado: (2021)

Assessing taxane-associated adverse events using the FDA adverse event reporting system database
por: Lao, Dong-Hui, et al.
Publicado: (2021)

Cardiac Events Potentially Associated to Remdesivir: An Analysis from the European Spontaneous Adverse Event Reporting System
por: Rafaniello, Concetta, et al.
Publicado: (2021)

A Standardized Dataset of a Spontaneous Adverse Event Reporting System
por: Khaleel, Mohammad Ali, et al.
Publicado: (2022)

Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor
por: Ali, Ayad K
Publicado: (2011)

Spontaneous Reporting on Adverse Events by Consumers in the United States: An Analysis of the Food and Drug Administration Adverse Event Reporting System Database
por: Toki, Tadashi, et al.
Publicado: (2018)

Pattern of adverse events induced by aflibercept and ranibizumab: A nationwide spontaneous adverse event reporting database, 2007–2016
por: Ha, Dongmun, et al.
Publicado: (2019)

META-INSTI: metabolic adverse events following integrase strand transfer inhibitor administration in spontaneous adverse event reports
por: Murray, Milena M, et al.
Publicado: (2023)

Adverse events of the yellow fever vaccine in chronic urticaria: evaluation of patients treated or not with omalizumab compared to healthy individuals()()
por: Almeida, Laura Ramos de, et al.
Publicado: (2021)

Assessment of factors associated with completeness of spontaneous adverse event reporting in the United States: A comparison between consumer reports and healthcare professional reports
por: Toki, Tadashi, et al.
Publicado: (2019)

Case Report: Omalizumab for Chronic Spontaneous Urticaria in Pregnancy
por: Liao, Shuang-Lu, et al.
Publicado: (2021)

106. META-INSTI: Metabolic Adverse Events Following Integrase Strand Transfer Inhibitor Administration in Spontaneous Adverse Event Reports
por: Murray, Milena M, et al.
Publicado: (2020)

Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting
por: Piccinni, Carlo, et al.
Publicado: (2011)

Spontaneously Reported Hepatic Adverse Drug Events in Korea: Multicenter Study
por: Kwon, Hee, et al.
Publicado: (2012)

Hematological Events Potentially Associated with CDK4/6 Inhibitors: An Analysis from the European Spontaneous Adverse Event Reporting System
por: Martins, Vera, et al.
Publicado: (2023)

Anaphylaxis Associated With Allergen Specific Immunotherapy, Omalizumab, and Dupilumab: A Real World Study Based on the US Food and Drug Administration Adverse Event Reporting System
por: Bian, Sainan, et al.
Publicado: (2021)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

Relating Spontaneously Reported Extrapyramidal Adverse Events to Movement Disorder Rating Scales
por: Widschwendter, Christian G., et al.
Publicado: (2015)

Sex differences in spontaneous reports on adverse drug events for common antihypertensive drugs
por: Rydberg, Diana M, et al.
Publicado: (2018)

Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS
por: Tian, Xiaojiang, et al.
Publicado: (2022)

Evaluation of lung adverse events with nivolumab using the spontaneous reporting system in Japan
por: Kanbayashi, Yuko, et al.
Publicado: (2023)

Assessing the association between dipeptidyl peptidase-4 inhibitors use and celiac disease through drug adverse event reporting
por: Li, Dandan, et al.
Publicado: (2020)

Gender differences in spontaneous adverse event reports associated with zolpidem in South Korea, 2015–2019
por: Joung, Kyung-In
Publicado: (2023)

OMALIZUMAB IN TREATMENT-RESISTANT CHRONIC SPONTANEOUS URTICARIA
por: Godse, Kiran V
Publicado: (2011)

Profile of omalizumab in the treatment of chronic spontaneous urticaria
por: Labrador-Horrillo, Moises, et al.
Publicado: (2015)

Systematic Analysis of Adverse Event Reports for Sex Differences in Adverse Drug Events
por: Yu, Yue, et al.
Publicado: (2016)

Omalizumab for the Treatment of Chronic Spontaneous Urticaria: Association Between Body Mass Index and Outcome
por: Russo, Irene, et al.
Publicado: (2022)

A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
por: Zou, Shu-peng, et al.
Publicado: (2023)

Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases
por: Nomura, Kaori, et al.
Publicado: (2015)

Assessing the Association Between GLP-1 Receptor Agonist Use and Diabetic Retinopathy Through the FDA Adverse Event Reporting System
por: Wang, Tiansheng, et al.
Publicado: (2019)

Assessing the Association Between Dipeptidyl Peptidase 4 Inhibitor Use and Inflammatory Bowel Disease Through Drug Adverse Event Reporting
por: Wang, Tiansheng, et al.
Publicado: (2019)

Exploration of the Association Rules Mining Technique for the Signal Detection of Adverse Drug Events in Spontaneous Reporting Systems
por: Wang, Chao, et al.
Publicado: (2012)

Spontaneously reported adverse events following COVID-19 basic and booster immunizations in the Netherlands
por: van der Boor, Saskia C., et al.
Publicado: (2023)

Commentary: Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS
por: Schilder, Jeanne M., et al.
Publicado: (2023)

Impact of the COVID-19 pandemic on the spontaneous reporting and signal detection of adverse drug events
por: Montes-Grajales, Diana, et al.
Publicado: (2023)

Assessment of costs associated with adverse events in patients with cancer
por: Wong, William, et al.
Publicado: (2018)

The temporal relationship between RotaTeq immunization and intussusception adverse events in the Vaccine Adverse Event Reporting System (VAERS)
por: Geier, David A., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_j51imfd63fr1q58hkc6g39f99r